Computed Tomography-guided Percutaneous Permanent Iodine-125 Implantation for Patients with Malignant Osseous Tumors

Wang, Weiyu; Wu, Lijian

doi:10.1177/1578.17208

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, percutaneous 125 I seed implantation has been proposed as an alternative or retreatment option for recurrent spinal primary tumors [38]. In addition, this approach was recently described for the treatment of malignant osseous tumors [39]. …”

Section: Discussionmentioning

confidence: 99%

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

et al. 2016

View full text Add to dashboard Cite

BackgroundComplete resection of pelvic bone tumors, especially recurrent and metastatic ones, is often impossible to achieve using conventional surgery. This study aimed to assess the benefits and adverse effects of computed tomography (CT)-guided radioiodine (125I) brachytherapy for inoperable recurrent and metastatic bone tumors of the pelvis.MethodsThis was a retrospective study of 22 patients with confirmed pelvic bone tumors (10 females and 12 males; 15–84 years; 21 with primary pelvic tumor and one with pelvic metastasis). CT-guided 125I brachytherapy was performed using 9–21 125I seeds (radioactivity of 0.5–0.7 mCi). Seed implantation was validated by postoperative CT scanning. Complications, pain, survival, and CT-estimated tumor size were carried out to evaluate the therapeutic benefits.ResultsPostoperative CT scans revealed satisfactory 125I seed implantation, and the radiation dose delivered to 90% of the target area (D90) was higher than the prescription dose (PD). No obvious complications were observed. Pain was reported by 19 of 22 patients, but 17 reported pain relief after implantation. Follow-up ranged 8–27 (median, 19) months. Tumor size was reduced in 11 patients within 1 month after surgery, nine patients showed no change, and tumor size increased in two patients. Finally, 1- and 2-year survival was 81.8 and 45.5%, respectively; 1- and 2-year local tumor control rates were 59.1 and 36.4%, respectively.Conclusions 125I seed implantation significantly reduced bone tumor size and relieved pain, with a low complication rate. These findings suggest that 125I brachytherapy treatment could be a useful palliative approach for pelvic bone tumor treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Computed Tomography-guided Percutaneous Permanent Iodine-125 Implantation for Patients with Malignant Osseous Tumors

Abstract: Computed tomography-guided 125I implantation is a safe, effective and feasible method in the treatment of patients with malignant osseous tumors.

Cited by 1 publication

References 28 publications

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

Contact Info

Product

Resources

About